TAC-100 is under clinical development by Triumvira Immunologics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAC-100 overview

TAC-01HER2 is under development for the treatment of HER2-positive solid tumors including breast cancer, pancreatic cancer, endometrial cancer, ovarian cancer, colorectal cancer, esophagus cancer, gastric cancer, gallbladder cancer and gastroesophageal (GE) junction carcinomas. It is administered by intravenous route. The drug candidate is developed based on TAC technology where T-cells are engineered to express T-cell Antigen Coupler (TAC) receptor. It acts by targeting cells expressing HER2 (human epidermal growth factor receptor) and cells expressing Claudin 18.2 (CLDN18.2). It was also under development for the treatment of glioblastoma multiforme, ovarian cancer, and sarcoma.

See Also:

Triumvira Immunologics overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Triumvira Immunologics (Triumvira) is a biopharmaceutical company involved in developing novel cancer therapies. The company uses chimeric antigen receptors and engineered T-cell receptors for development of the therapies. Triumvira is involved in investigation of mechanism in which TAC directs the engineered T-cells to target antigen and activates the T-cells after binding with antigen. The company’s product pipeline include TAC01-HER2 and TAC02-HER2 for autologous and allogenic solid tumors which are in initial stages of development. It also investigates on B cell maturation antigen (BCMA) for treatment of Multiple myeloma which is currently in initial phases of clinical trials. The company operates research facility in Hamilton, Ontario, Canada. Triumvira is headquartered in Austin, Texas, the US.

For a complete picture of TAC-100’s drug-specific PTSR and LoA scores, buy the report here.